Symbols

NCNA

Nucana·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Stock Price Surged Significantly

Ample Liquidity

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NCNA

Nucana Plc

A company that develops and commercializes novel, plant-based protein ingredients for the food industry

Industry

Pharmaceutical

Established Date

01/28/1997

Listing Date

09/28/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.nucana.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

NuCana plc 3 Lochside Way Edinburgh EH12 9DT United Kingdom

Business

Introduction

Nucana Plc is a private company incorporated in England and Wales on 28 January 1997. NuCana Plc is a clinical-stage biopharmaceutical company developing a range of new drugs for the treatment of cancer patients. NuCana is taking advantage of phosphamide chemistry to develop a new class of drugs called ProTides. These compounds are expected to improve cancer treatment by improving the efficacy and safety of a variety of existing standard therapies.

Company Financials

EPS

NCNA has released its 2025 Q4 earnings. EPS was reported at 0, versus the expected -2.69, beating expectations. The chart below visualizes how NCNA has performed over recent quarters, highlighting trends in earnings surprises.